EUVIMEDEUVIMED entdecken
Crossref

Evaluation of nintedanib efficacy: Attenuating the lens fibrosis in vitro and vivo

Xuefei Ding, Peilin Yue, Xiaohe Li, Yuxuan Jia, Rui Fang, Enjie Li, Xi Wu, Honggang Zhou, Xudong Song

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xuefei Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Tongren Hospital, Beijing 100730, China; Capital Medical University, Beijing 100730, China. Hauptthemen laut MEDLINE: Indoles, Lens, Crystalline, Transforming Growth Factor beta2, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Organ fibrosis is a huge challenge in clinic. There are no drugs for fibrotic cataracts treatments in clinic. Nintedanib is approved by the FDA for pulmonary fibrosis treatments. This study aims to investigate the efficacy and mechanism of nintedanib on fibrotic cataracts. METHODS: Drug efficacy was validated through TGFβ2-induced cell models and injury-induced anterior subcapsular cataract (ASC) mice. A slit lamp and the eosin staining technique were applied to access the degree of capsular fibrosis. The CCK-8 assay was used to evaluate the toxicity and anti-proliferation ability of the drug. The cell migration was determined by wound healing assay and transwell assay. The anti-epithelial mesenchymal transition (EMT) and anti-fibrosis efficacy were evaluated by qRT-PCR, immunoblot, and immunofluorescence. The inhibition of nintedanib to signaling pathways was certified by immunoblot. RESULTS: Nintedanib inhibited the migration and proliferation of TGFβ2-induced cell models. Nintedanib can also repress the EMT and fibrosis of the lens epithelial cells. The intracameral injection of nintedanib can also allay the anterior subcapsular opacification in ASC mice. The TGFβ2/ Smad and non-Smad signaling pathways can be blocked by nintedanib in vitro and in vivo. CONCLUSION: Nintedanib alleviates fibrotic cataracts by suppressing the TGFβ2/ Smad and non-Smad signaling pathways. Nintedanib is a potential drug for lens fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndolesLens, CrystallineTransforming Growth Factor beta2Epithelial-Mesenchymal TransitionCell MovementFibrosisAnimalsMiceHumansCell ProliferationCell LineSignal TransductionCataractMice, Inbred C57BLEpithelial CellsDisease Models, AnimalAntifibrotic AgentsMale

Stichwörter der Autor:innen

CataractEpithelial-mesenchymal transitionFibrosisNintedanibTGFβ2

Substanzen

nintedanibIndolesTransforming Growth Factor beta2Antifibrotic Agents

Autor:innen und Institutionen

  • Beijing Tongren Hospital, Beijing 100730, China; Capital Medical University, Beijing 100730, China.
  • The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nan Kai University, Tianjin, China.
  • The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nan Kai University, Tianjin, China. Electronic address: honggang.zhou@nankai.edu.cn.
  • Beijing Tongren Hospital, Beijing 100730, China; Capital Medical University, Beijing 100730, China; Beijing Tongren Eye Center, Beijing 100730, China; Beijing Ophthalmology&Visual Sciences Key Lab, Beijing 100730, China…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ding, X., Yue, P., Li, X., Jia, Y., Fang, R., Li, E., Wu, X., Zhou, H., & Song, X. (2024). Evaluation of nintedanib efficacy: Attenuating the lens fibrosis in vitro and vivo. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112334

Vancouver

Ding X, Yue P, Li X, Jia Y, Fang R, Li E, et al. Evaluation of nintedanib efficacy: Attenuating the lens fibrosis in vitro and vivo. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112334

BibTeX
@article{Ding2024,
  author = {Ding, Xuefei and Yue, Peilin and Li, Xiaohe and Jia, Yuxuan and Fang, Rui and Li, Enjie and Wu, Xi and Zhou, Honggang and Song, Xudong},
  title = {Evaluation of nintedanib efficacy: Attenuating the lens fibrosis in vitro and vivo},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112334}
}
Kostenlos starten →